• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Pharmacogenomics and Personalized Medicine >Pharmacogenomics of statins: understanding susceptibility to adverse effects
【24h】

Pharmacogenomics of statins: understanding susceptibility to adverse effects

机译：他汀类药物的药物基因组学：了解不良反应的易感性

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Statins are a cornerstone of the pharmacologic treatment and prevention of atherosclerotic cardiovascular disease. Atherosclerotic disease is a predominant cause of mortality and morbidity worldwide. Statins are among the most commonly prescribed classes of medications, and their prescribing indications and target patient populations have been significantly expanded in the official guidelines recently published by the American and European expert panels. Adverse effects of statin pharmacotherapy, however, result in significant cost and morbidity and can lead to nonadherence and discontinuation of therapy. Statin-associated muscle symptoms occur in ~10% of patients on statins and constitute the most commonly reported adverse effect associated with statin pharmacotherapy. Substantial clinical and nonclinical research effort has been dedicated to determining whether genetics can provide meaningful insight regarding an individual patient’s risk of statin adverse effects. This contemporary review of the relevant clinical research on polymorphisms in several key genes that affect statin pharmacokinetics (eg, transporters and metabolizing enzymes), statin efficacy (eg, drug targets and pathways), and end-organ toxicity (eg, myopathy pathways) highlights several promising pharmacogenomic candidates. However, SLCO1B1 521C is currently the only clinically relevant pharmacogenetic test regarding statin toxicity, and its relevance is limited to simvastatin myopathy.
机译：他汀类药物是药物治疗和预防动脉粥样硬化性心血管疾病的基石。动脉粥样硬化疾病是全世界死亡率和发病率的主要原因。他汀类药物是最常用的处方药物之一，在美国和欧洲专家小组最近发布的官方指南中，他汀类药物的处方适应症和目标患者群已得到显着扩展。但是，他汀类药物疗法的不良作用会导致巨大的成本和发病率，并可能导致不依从性和治疗中止。与他汀类药物相关的肌肉症状发生在约10％的他汀类药物患者中，构成了与他汀类药物治疗相关的最常见的不良反应。大量的临床和非临床研究工作致力于确定遗传学是否可以提供有关单个患者他汀类药物不良反应风险的有意义的见解。这篇对有关影响他汀药代动力学（例如转运蛋白和代谢酶），他汀药效（例如药物靶点和途径）和终末器官毒性（例如肌病途径）的几个关键基因多态性的相关临床研究的当代综述一些有希望的药物基因组学候选者。但是，SLCO1B1 521C是目前有关他汀类药物毒性的唯一临床相关药物遗传学测试，其相关性仅限于辛伐他汀肌病。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号